Weekly versus three weeks chemotherapy for advanced ovarian cancer: A meta-analysis

Claudia Marchetti, Francesca De Felice, Angela Musella, Innocenza Palaia, Marco Monti, Daniela Musio, Ludovico Muzii, Vincenzo Tombolini, Pierluigi Benedetti Panici

Risultato della ricerca: Contributo in rivistaArticolo in rivista


Aim: Three weeks paclitaxel and carboplatin has been considered the standard of care for primary treatment of ovarian cancer (OC). Whether weekly therapy will further improve the clinical outcomes or not is still unclear. We conducted a metaanalysis to compare the two regimens. Method: Articles were selected with a systematic approach, using PubMed databases. Trials concerning comparison between carboplatin plus weekly paclitaxel (dose-dense regimen) and carboplatin plus paclitaxel every 3 weeks were considered. Outcomes included overall survival (OS), progression free survival (PFS) and severe acute toxicity. Results: Dose-dense regimen was associated with significant improvement of PFS compared with standard schedule, with HR of 0.73 (95% CI 0.61-0.88, p = 0.001). There was no difference in OS between treatment regimens (HR 0.95, 95% CI 0.77- 1.16, p=0.06), as well as in term of severe acute toxicity. Conclusion: Dose-dense regimen is superior to standard schedule in terms of PFS. Further studies are necessary to firmly confirm this evidence in advanced OC treatment.
Lingua originaleEnglish
pagine (da-a)58709-58715
Numero di pagine7
Stato di pubblicazionePubblicato - 2016


  • Carboplatin
  • Dose-dense
  • Ovarian cancer
  • Paclitaxel
  • Weekly


Entra nei temi di ricerca di 'Weekly versus three weeks chemotherapy for advanced ovarian cancer: A meta-analysis'. Insieme formano una fingerprint unica.

Cita questo